AU2866400A - Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors - Google Patents

Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors Download PDF

Info

Publication number
AU2866400A
AU2866400A AU28664/00A AU2866400A AU2866400A AU 2866400 A AU2866400 A AU 2866400A AU 28664/00 A AU28664/00 A AU 28664/00A AU 2866400 A AU2866400 A AU 2866400A AU 2866400 A AU2866400 A AU 2866400A
Authority
AU
Australia
Prior art keywords
dihydroxy open
open acid
statin
simvastatin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28664/00A
Other languages
English (en)
Inventor
Edward J.J. Grabowski
Paul J. Reider
Richard D Tillyer
Jose M. Vega
Feng Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2866400A publication Critical patent/AU2866400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU28664/00A 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors Abandoned AU2866400A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US60123227 1999-03-08
US26474499A 1999-03-09 1999-03-09
US09264744 1999-03-09
PCT/US2000/002626 WO2000053173A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Publications (1)

Publication Number Publication Date
AU2866400A true AU2866400A (en) 2000-09-28

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28664/00A Abandoned AU2866400A (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Country Status (9)

Country Link
EP (1) EP1161236A1 (es)
JP (2) JP2002538202A (es)
AR (1) AR022856A1 (es)
AU (1) AU2866400A (es)
CA (1) CA2364253A1 (es)
CO (1) CO5150193A1 (es)
PE (1) PE20001559A1 (es)
SV (1) SV2002000036A (es)
WO (1) WO2000053173A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
EP1324972A4 (en) * 2000-09-06 2004-06-30 Merck & Co Inc OPEN-CHAIN DIHYDROXY ACID SALT BY SIMVASTATIN
SK4112003A3 (en) * 2000-10-12 2004-01-08 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
EP1425287A4 (en) * 2001-08-16 2005-09-07 Teva Pharma PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINES
AU2003206251B2 (en) * 2002-01-09 2008-03-13 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2015055857A1 (en) * 2013-10-18 2015-04-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
EP3624789B1 (en) 2017-05-15 2024-09-25 University of Cincinnati Compositions comprising metabolites of simvastatin for use in repairing or retarding damage to avascular cartilaginous tissue by direct administration to the avascular tissue
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
DE122011000014I1 (de) * 1995-12-22 2011-11-03 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
JP2000256191A (ja) 2000-09-19
PE20001559A1 (es) 2001-01-16
JP2002538202A (ja) 2002-11-12
EP1161236A1 (en) 2001-12-12
CA2364253A1 (en) 2000-09-14
WO2000053173A1 (en) 2000-09-14
AR022856A1 (es) 2002-09-04
SV2002000036A (es) 2002-02-05
CO5150193A1 (es) 2002-04-29

Similar Documents

Publication Publication Date Title
US6569461B1 (en) Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU764048B2 (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
AU2866400A (en) Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
EP1677767B1 (en) Crystalline form of gamma-aminobutyric acid analog
ES2351471T3 (es) Nueva sal y polimorfo de inhibidores de dpp-iv.
US9556133B2 (en) Polycyclic LPA1 antagonist and uses thereof
AU2010221167B2 (en) Oral dosage forms having a high loading of a gabapentin prodrug
HRP20030104A2 (en) Therapeutic combination
US20030176501A1 (en) Dihydroxy open-acid salt of simvastatin
EP3666750A1 (en) Crystalline form of bempedoic acid
EP1036563A1 (en) Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
CN101328156B (zh) 含1,3二杂五元环的异羟肟酸类衍生物及其用途
US9969674B2 (en) MMF-derivatives of ethyleneglycols
ES2281594T3 (es) Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre.
US11795180B2 (en) Formulation of a pan-JAK inhibitor
CN110183348A (zh) N-(3-硝基-4-烷氧基苯甲酰基)氨基酸类化合物、制备方法及其用途